Riparian Pharmaceuticals inks license and research agreement with Pfizer for cardiovascular programs
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Fully equipped labs with 75-member team set-up and made operational in <100 days
Study efficacy measures will include the expression of dystrophin protein and motor function.
Subscribe To Our Newsletter & Stay Updated